United Therapeutics Co. (NASDAQ:UTHR) Expected to Post Earnings of $3.79 Per Share

Wall Street brokerages expect that United Therapeutics Co. (NASDAQ:UTHR) will post earnings per share (EPS) of $3.79 for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for United Therapeutics’ earnings, with estimates ranging from $3.60 to $3.91. United Therapeutics posted earnings of $2.19 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 73.1%. The business is expected to issue its next quarterly earnings results on Wednesday, February 23rd.

According to Zacks, analysts expect that United Therapeutics will report full year earnings of $11.37 per share for the current fiscal year, with EPS estimates ranging from $11.13 to $11.60. For the next year, analysts anticipate that the business will report earnings of $15.06 per share, with EPS estimates ranging from $12.34 to $16.34. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, November 3rd. The biotechnology company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.37 by $0.05. The business had revenue of $444.70 million for the quarter, compared to analyst estimates of $421.45 million. United Therapeutics had a return on equity of 12.93% and a net margin of 27.94%. The firm’s revenue was up 17.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.84 EPS.

In other news, CEO Martine A. Rothblatt sold 3,083 shares of the stock in a transaction on Monday, November 8th. The stock was sold at an average price of $200.94, for a total transaction of $619,498.02. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction on Thursday, September 2nd. The stock was sold at an average price of $210.94, for a total value of $1,265,640.00. Following the sale, the executive vice president now directly owns 42,369 shares in the company, valued at $8,937,316.86. The disclosure for this sale can be found here. Insiders have sold a total of 47,715 shares of company stock worth $9,539,657 over the last three months. 12.10% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Clean Yield Group bought a new position in United Therapeutics in the second quarter valued at about $27,000. Daiwa Securities Group Inc. increased its stake in shares of United Therapeutics by 75.0% in the third quarter. Daiwa Securities Group Inc. now owns 154 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 66 shares during the period. Eaton Vance Management acquired a new stake in United Therapeutics during the first quarter worth approximately $30,000. FORA Capital LLC acquired a new stake in United Therapeutics during the second quarter worth approximately $31,000. Finally, Denali Advisors LLC grew its stake in United Therapeutics by 100.0% during the second quarter. Denali Advisors LLC now owns 200 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 94.12% of the company’s stock.

Shares of UTHR stock traded down $1.40 during trading on Thursday, reaching $200.18. 505,387 shares of the company’s stock were exchanged, compared to its average volume of 363,155. The company has a quick ratio of 7.15, a current ratio of 7.46 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $9.02 billion, a PE ratio of 20.28 and a beta of 0.55. United Therapeutics has a twelve month low of $129.43 and a twelve month high of $216.90. The firm’s fifty day moving average price is $194.96 and its 200-day moving average price is $192.76.

About United Therapeutics

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.

See Also: What are gap-up stocks?

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.